Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB014 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | Dose Level A of BIIB014 |
| 2 | PLACEBO_COMPARATOR | Dose Level B of BIIB014 |
| 3 | PLACEBO_COMPARATOR | Dose Level C of BIIB014 |
| 4 | PLACEBO_COMPARATOR | Dose Level D of BIIB014 |
| Name | Type | Description |
|---|---|---|
| BIIB014 | DRUG | oral administration of BIIB014 per dose, schedule,and duration specified in protocol |
| Placebo | DRUG | Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014 |
Inclusion Criteria: * Must give written informed consent and any authorizations required by local law. * Must carry a diagnosis of idiopathic Parkinson's Disease(PD), without any other known or suspected cause of parkinsonism, according to the UK Parkinson's Disease Society Brain Bank Clinical Diag...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
BIIB014 is an investigational small molecule developed by Biogen Inc. (ticker BIIB) for Parkinson's disease. It is a neurology asset that has been studied in Phase 2 clinical trials. BIIB014 is also known as BIIB014 50mg. It has not been approved by the FDA and remains in clinical development.
BIIB014 is being studied for the treatment of Parkinson's disease. Two Phase 2 trials evaluated it in early-stage Parkinson's disease and in combination with levodopa in moderate to late stage Parkinson's disease. Both studies are completed, and the drug remains investigational rather than approved for prescribing.
BIIB014 is developed by Biogen Inc., which trades on the Nasdaq under the ticker BIIB. Biogen is the sponsor of the clinical program studying BIIB014 in Parkinson's disease. The drug is an investigational small molecule and is not currently an approved commercial product.
BIIB014 is in Phase 2 development. Two Phase 2 dose-finding safety studies have been completed, one in early-stage Parkinson's disease and one in combination with levodopa in moderate to late stage Parkinson's disease. No active trials are currently listed, and the drug is not FDA approved.
BIIB014 has been studied in two completed Phase 2 trials: NCT00442780, a dose-finding safety study in early-stage Parkinson's disease with 36 participants, and NCT00438607, a dose-finding safety study in combination with levodopa in moderate to late stage Parkinson's disease with 83 participants. Both were randomized, double-blind, and placebo-controlled.